Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY)

C. L. Vogel; J. M. Denefrio; L. C. Padgett; M. A. Silverman

Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY)

C. L. Vogel, J. M. Denefrio, L. C. Padgett, M. A. Silverman

Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

In a phase I trail, 2,3-dihydro-1H-imidazo[1,2-b]pyrazole was administered iv weekly at doses ranging from 0.1 to 3.0 g/m²/wk to patients with refractory metastatic solid tumors. Although gastrointestinal toxicity was tolerable and neither granulocyte nor platelet toxicity was seen, significant dose-limiting hemolysis was encountered at doses of 1.5 g/m²/wk. While no definite tumor regressions were seen in the 32 patients evaluable for response, two patients (squamous cell carcinoma of lung and tonsil) had clinically useful improvement.

Original language	English (US)
Pages (from-to)	1153-1156
Number of pages	4
Journal	Cancer Treatment Reports
Volume	64
Issue number	10-11
State	Published - Dec 1 1980

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{b35d86f2a6a34bccbebadd1d1467b154,

title = "Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY)",

abstract = "In a phase I trail, 2,3-dihydro-1H-imidazo[1,2-b]pyrazole was administered iv weekly at doses ranging from 0.1 to 3.0 g/m2/wk to patients with refractory metastatic solid tumors. Although gastrointestinal toxicity was tolerable and neither granulocyte nor platelet toxicity was seen, significant dose-limiting hemolysis was encountered at doses of 1.5 g/m2/wk. While no definite tumor regressions were seen in the 32 patients evaluable for response, two patients (squamous cell carcinoma of lung and tonsil) had clinically useful improvement.",

author = "Vogel, {C. L.} and Denefrio, {J. M.} and Padgett, {L. C.} and Silverman, {M. A.}",

year = "1980",

month = dec,

day = "1",

language = "English (US)",

volume = "64",

pages = "1153--1156",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "10-11",

}

TY - JOUR

T1 - Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY)

AU - Vogel, C. L.

AU - Denefrio, J. M.

AU - Padgett, L. C.

AU - Silverman, M. A.

PY - 1980/12/1

Y1 - 1980/12/1

N2 - In a phase I trail, 2,3-dihydro-1H-imidazo[1,2-b]pyrazole was administered iv weekly at doses ranging from 0.1 to 3.0 g/m2/wk to patients with refractory metastatic solid tumors. Although gastrointestinal toxicity was tolerable and neither granulocyte nor platelet toxicity was seen, significant dose-limiting hemolysis was encountered at doses of 1.5 g/m2/wk. While no definite tumor regressions were seen in the 32 patients evaluable for response, two patients (squamous cell carcinoma of lung and tonsil) had clinically useful improvement.

AB - In a phase I trail, 2,3-dihydro-1H-imidazo[1,2-b]pyrazole was administered iv weekly at doses ranging from 0.1 to 3.0 g/m2/wk to patients with refractory metastatic solid tumors. Although gastrointestinal toxicity was tolerable and neither granulocyte nor platelet toxicity was seen, significant dose-limiting hemolysis was encountered at doses of 1.5 g/m2/wk. While no definite tumor regressions were seen in the 32 patients evaluable for response, two patients (squamous cell carcinoma of lung and tonsil) had clinically useful improvement.

UR - http://www.scopus.com/inward/record.url?scp=0019253952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019253952&partnerID=8YFLogxK

M3 - Article

C2 - 7459903

AN - SCOPUS:0019253952

VL - 64

SP - 1153

EP - 1156

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10-11

ER -

Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY)

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this